Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are enjoying peppermint mocha for now. Feel free, of course, to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today …

Sanofi (SNY) acknowledged suffering from low uptake for a new cholesterol drug and concerns about a dengue vaccine, but expressed confidence its pipeline of new products would support long-term growth, Reuters reports. The drug maker, which is battling to contain the fallout from a safety row in the Philippines over its dengue vaccine, tried to buoy investors by pointing to nine regulatory submissions that should be filed in the next 18 months.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy